Showing results (1791-1800 of 1,960) with videos related to

Sort By:
Pageof 196
American Journal of Hematology|June 1, 2010
A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myelomaAngela Dispenzieri, Gregory A Wiseman, Martha Q Lacy, et al.
Blood Cancer Journal|January 29, 2022
Chronic lymphocytic leukemia (CLL) with Reed-Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter?Rebecca L King, Alia Gupta, Paul J Kurtin, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|July 9, 2017
Deguelin exerts potent nematocidal activity via the mitochondrial respiratory chainSarah Preston, Pasi K Korhonen, Laurent Mouchiroud, et al.
Blood Cancer Journal|August 29, 2015
Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphomaA J Novak, Y W Asmann, M J Maurer, et al.
British Journal of Haematology|November 18, 2020
Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinibJorge J Castillo, Jithma P Abeykoon, Joshua N Gustine, et al.
Lancet (London, England)|October 6, 2012
Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trialRenato D Lopes, Sana M Al-Khatib, Lars Wallentin, et al.
Journal of Neuroendocrinology|December 27, 2024
Earlier diagnosis of small intestine neuroendocrine tumours (SI-NETs) through transformation of the South Wales NET serviceHarriet L Gould, Kapish Amin, Thanos Karategos, et al.
Blood Advances|August 2, 2023
Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 studyStephen M Ansell, Paul J Bröckelmann, Gottfried von Keudell, et al.
Journal of Neuro-Oncology|July 6, 2019
Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastomaAndrew B Lassman, Kenneth D Aldape, Peter J Ansell, et al.
Neuro-Oncology Advances|July 10, 2020
EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligandYouri Hoogstrate, Wies Vallentgoed, Johan M Kros, et al.
Pageof 196